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Abstract
Background: Hypofractionated radiotherapy has been used for the treatment of AVMs and brain
metastases. Hypofractionation necessitates the use of a relocatable stereotactic frame that has to
be applied on several occasions. The stereotactic frame needs to have a high degree of
reproducibility, and patient positioning is crucial to achieve a high accuracy of the treatment.
Methods: In this study we have, by radiological means, evaluated the reproducibility of the
isocenter in consecutive treatment sessions using the Fixster frame. Deviations in the X, Y and Z-
axis were measured in 10 patients treated with hypofractionated radiotherapy.
Results: The mean deviation in the X-axis was 0.4 mm (range -2.1 – 2.1, median 0.7 mm) and in
the Y-axis -0.3 mm (range -1.4 – 0.7, median -0.2 mm). The mean deviation in the Z-axis was -0.6
(range -1.4 – 1.4, median 0.0 mm).
Conclusion: There is a high degree of reproducibility of the isocenter during successive treatment
sessions with HCSRT using the Fixster frame for stereotactic targeting. The high reducibility
enables a safe treatment using hypofractionated stereotactic radiotherapy.
Background
Hypofractionated stereotactic radiotherapy (HCSRT) is a
method of delivering stereotactic irradiation in a few frac-
tions using a relocatable stereotactic frame. This treatment
is currently used for the treatment of arteriovenous mal-
formations (AVMs) [1-4] and brain metastases [5,6].
HCSRT may be more appropriate than single fraction
radiosurgery (SRS) for the treatment of large lesions or
lesions located in eloquent areas. HCSRT enables the
delivery of a higher total dose than possible with SRS
without an increased risk of radionecrosis [1]. Fraction-
ated stereotactic radiotherapy may also provide a radio-
biological advantage over SRS in the treatment of
malignant tumours [7]. HCSRT has been used for the
treatment of AVMs and single or oligo brain metastases
since 1986 at Umeå university Hospital. Results in terms
of obliteration of AVMs has been evaluated and found to
be comparable with SRS even though our AVMs were
larger than in most series with SRS [1]. The standard treat-
ment schedule for AVMs is 35 Gy in 5 fractions and for
brain metastases 40 Gy in 5 fractions. The dose was nor-
malized and specified to the center of the target and the
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90% isodose line always encompassed the planning target
volume. The procedure of hypofractionation and the relo-
catable stereotactic frame used for AVMs has been
described earlier [1]. In order to deliver a hypofraction-
ated treatment it is necessary to use a relocatable stereotac-
tic frame. The relocatable Fixster frame [8,9] has been
used by us for the treatment of brain metastases [6]. The
accuracy of the stereotactic treatment will among other
factors depend on the reproducibility of the stereotactic
frame and the positioning of the patient. It is necessary
that the frame and the patient can be positioned in the
exact same way for each treatment session in order to
deliver the irradiation according to the dose plan. Other
stereotactic frames used for fractionated radiotherapy are
the Laitinen stereoadapter (LS) and the Gill-Thomas-Cos-
man frame (GTC). These frames have reported a high level
of reproducibility with a geometrical accuracy of less than
1 mm for the LS [10,11] and a overall accuracy of 1.7 ± 0.7
mm for the GTC [12]. In the case of the Fixster system
there is no study that has investigated the accuracy of the
frame regarding reproducibility in a clinical treatment sit-
uation. The Fixster head fixation system was first
described by Greitz et al., and in the original paper it was
reported to have a maximum deviation of 2–3 mm in
terms of reproducibility of the frame [9]. According to
Bergström et al., the accuracy for coordinate determina-
tions in a phantom had a maximum error of 1 mm [8]. In
this study we have evaluated the clinical reproducibility of
the total set up procedure in consecutive treatment ses-
sions of patients with brain metastases using the relocata-
ble Fixster frame.
Methods
Ten patients diagnosed with cerebral metastases were
treated with HCSRT using the Fixster frame for stereotactic
targeting of the lesion in every treatment session. The local
ethical committee at the Umeå University Hospital
approved this study, and all patients had given an
informed consent in participating in this study. Before
treatment a stereotactic CT examination with the Fixster
frame was performed in all patients for doseplanning [6].
During treatment the patients were positioned on the
coach of a Linear accelerator (Varian 2300 C/D). The rota-
tion center of the linear accelerator was positioned in the
isocenter of the dose plan by alignment of the calibrated
narrow laser cross lines in the treatment room to marked
positions on the side plates of the frame (Fig 1). A careful
and precise test of reproducibility was not possible to per-
form in the treatment room, and was therefore performed
at the simulator where an X-ray facility was available (the
Oldelft MC). After each of three consecutive treatment ses-
sions the patients had the Fixster frame carefully applied
and positioned in the simulator room. Indicators were
mounted on the side plates of the frame to facilitate the
evaluation. Two orthogonal plain X-ray images; lateral
and anterioposterior views (Fig. 2), were taken with the
Fixster frame in position. The first set of X-ray images was
used as a template, and the center of the target was care-
fully marked. A pencil was used to mark the inner table of
the skull bone and bone landmarks on the lateral and
anterioposterior views; the orbital rim, the sphenoid sinus
and the sella. Images from the next two investigations
were marked in the same way and superimposed on the
corresponding projection. The deviation in X, Y, and Z
from the isocenter on the original investigation was meas-
ured and corrected with the magnification factor on the X-
ray images to achieve the real deviation. Deviation to the
right in the X-axis, laterality, was assigned positive values
and to the left negative values. Deviation in the frontal
direction in the Y-axis, anterio-posteriorly, was assigned a
positive value and a deviation the opposite direction a
negative value. Finally, in the Z-axis, cranio-caudal, devia-
tion caudally towards the skull base was assigned a posi-
tive value and deviation in the cranial direction was
assigned a negative value.
Results
The deviations in the X, Y and Z-axis are shown in Table 1
and Fig. 3. The mean deviation in the X-axis was 0.4 mm,
(range, -2.1 – 2.1, median, 0.7 mm) and in the Y-axis -0.3
mm (range, -1.4 – 0.7, median, -0.2 mm). The mean devi-
ation in the Z-axis was -0.6 mm (range, -1.4 – 1.4, median,
0.0 mm).
Discussion
There seems to be a high degree of reproducibility of the
isocenter after repetitive positioning of the Fixster frame
during treatment sessions with HCSRT. The largest devia-
tion was observed in the X-axis with a maximum devia-
tion of 2.1 mm at one occasion. The high accuracy and
precision of SRS as an alternative to HCSRT has previously
Patient in a treatment situation, the Fixster frame applied and  infrared beams indicating the isocenter Figure 1
Patient in a treatment situation, the Fixster frame applied and 
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been documented [13]. Even simulation of a multistage
treatment in a phantom using SRS shows a high accuracy
with a maximum error of 1 mm after sequential place-
ment of the Leksell stereotactic head frame [14]. There has
been an increased interest in HCSRT for the treatment of
brain metastases and AVMs as an alternative to SRS [3-5].
Treatment with HCSRT may allow the delivery of a higher
total dose than possible with SRS. There might be concern
that fractionation with a non-invasive relocatable stereo-
tactic frame and patient positioning for treatment may
compromise the precision of the treatment. In our treat-
ment of brain metastases we use a stereotactic frame that
has been described in previous publications. The Fixster
frame may also be used for other purposes such as treat-
ment of non-operable skull base meningeomas. At our
departments, however, we do not use a hypofractionated
schedule for this treatment due to the often close relation-
ship to eloquent structures including the optic nerve. In
these cases irradiation is delivered in 2 Gy fractions to a
total dose of 56 Gy. In our study deviations in the three
dimensions (X, Y and Z) are not solely a measurement of
the precision and reproducibility of the stereotactic frame
but include also the set up alignment for repeated treat-
ment sessions. Thus we have measured the maximum
deviation of the isocenter during successive simulated
treatment sessions. We believe that this is a more accurate
way to evaluate the precision in the treatment than to only
evaluate the reproducibility of the stereotactic frame itself.
The two most commonly used relocatable non-invasive
stereotactic frames used for fractionated radiotherapy are
the LS and the GTC. The reproducibility of the LS in
patient studies has proved to be less than 1 mm
[10,11,15]. The GTC frame has in two recent studies
shown a reproducibility with a mean error of 1.7 and 1.8
mm [12,16]. The reproducibility and accuracy of the Fix-
ster frame in a clinical treatment situation has not been
described previously. The maximum deviations after suc-
cessive mountings of the Fixster frame, including patient
positioning before treatment, seem to be in the range of
what has been reported for the other relocatable non-
invasive frames used for fractionated radiotherapy. Even
Orthogonal plain X-ray images; lateral and anterioposterior  views Figure 2
Orthogonal plain X-ray images; lateral and anterioposterior 
views.
Table 1: Deviation in the X, Y and Z axis.
Patients Dev X (mm) Dev Y (mm) Dev Z (mm)
1 -0.4 -0.4 -0.4
0.7 0.7 0.7
2 0.7 0.0 0.0
1.4 0.0 1.4
3 1.4 -1.4 0.0
0.0 0.7 -1.4
4 0.4 -1.4 -0.7
2.1 -0.7 0.7
5- 2 . 1 - 0 . 7 0 . 7
0.0 -0.7 -0.7
6 1.4 -1.4 -0.7
1.8 -0.7 -1.4
7- 2 . 1 - 0 . 7 1 . 4
1.1 -1.4 -0.7
8 0.7 0.7 0.0
0.7 0.0 0.7
9 0.7 0.7 0.0
0.0 0.7 0.0
10 0.0 0.0 0.0
0.0 0.0 -0.7
Three dimensional graph showing deviations in the X, Y and  Z-axis Figure 3
Three dimensional graph showing deviations in the X, Y and 
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in the case of a maximum error the targets should be cov-
ered by the margin added to generate the planning target
volume. A 2 mm margin is added to the nidus for AVMs,
and a 3 mm margin for brain metastases. There is of
course a risk that the positioning of the patient will be
more carefully done during an investigational assessment
than during routine treatment. However, using a non-
invasive stereotactic system one has always to be aware of
this issue and at all occasions be meticulous when posi-
tioning the patient.
Conclusion
There is a high degree of reproducibility in successive
treatment sessions with HCSRT using the Fixster frame for
stereotactic targeting. The isocenter show only a small
deviation in the X, Y and Z-axis after consecutive treat-
ment sessions including repetitive mounting of the Fixster
frame and patient positioning. Thus, hypofractionated
stereotactic radiotherapy using the non-invasive relocata-
ble Fixster frame shows a high accuracy despite the need
for repetitive application of a stereotactic frame and
patient positioning.
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